A
Ajay K. Nooka
Researcher at Emory University
Publications - 284
Citations - 8859
Ajay K. Nooka is an academic researcher from Emory University. The author has contributed to research in topics: Multiple myeloma & Medicine. The author has an hindex of 35, co-authored 218 publications receiving 6505 citations. Previous affiliations of Ajay K. Nooka include University of Texas MD Anderson Cancer Center & Icahn School of Medicine at Mount Sinai.
Papers
More filters
Journal ArticleDOI
Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma
Antonio Palumbo,Asher Chanan-Khan,Katja Weisel,Ajay K. Nooka,Tamás Masszi,Meral Beksac,Ivan Spicka,Vania Hungria,Markus Munder,Maria-Victoria Mateos,Tomer M Mark,Ming Qi,Jordan M. Schecter,Himal Amin,Xiang Qin,William Deraedt,Tahamtan Ahmadi,Andrew Spencer,Pieter Sonneveld +18 more
TL;DR: Among patients with relapsed or relapsed and refractory multiple myeloma, daratumumab in combination with bortezomib and dexamethasone resulted in significantly longer progression-free survival than borteonib and DexamethAsone alone and was associated with infusion-related reactions and higher rates of thrombocytopenia and neutropenia.
Journal ArticleDOI
Frequency and Risk Factors Associated With Osteonecrosis of the Jaw in Cancer Patients Treated With Intravenous Bisphosphonates
Ana O. Hoff,Bela B. Toth,Kadri Altundag,Marcella M. Johnson,Carla L. Warneke,Mimi Hu,Ajay K. Nooka,Gilbert Sayegh,Valentina Guarneri,Kimberly Desrouleaux,Jeffrey Cui,Andrea Adamus,Robert F. Gagel,Gabriel N. Hortobagyi +13 more
TL;DR: Osteonecrosis of the jaw has been reported in patients treated with bisphosphonates and the incidence and risk factors associated with this disorder have not been clearly defined.
Journal ArticleDOI
Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study.
Sagar Lonial,Hans C. Lee,Ashraf Badros,Suzanne Trudel,Ajay K. Nooka,Ajai Chari,Al-Ola Abdallah,Natalie S. Callander,Nikoletta Lendvai,Douglas W. Sborov,Attaya Suvannasankha,Katja Weisel,Lionel Karlin,Edward N. Libby,Bertrand Arnulf,Thierry Facon,Cyrille Hulin,K. Martin Kortüm,Paula Rodriguez-Otero,Saad Z. Usmani,Parameswaran Hari,Rachid Baz,Hang Quach,Philippe Moreau,Peter M. Voorhees,Ira Gupta,Axel Hoos,Eric Zhi,January Baron,Trisha Piontek,Eric Lewis,Roxanne C. Jewell,Elisha J. Dettman,Rakesh Popat,Simona Degli Esposti,Joanna Opalinska,Paul G. Richardson,Adam D. Cohen +37 more
TL;DR: Single-agent belantamab mafodotin shows anti-myeloma activity with a manageable safety profile in patients with relapsed or refractory multiple myeloma.
Journal ArticleDOI
Oral selinexor-dexamethasone for triple-class refractory multiple myeloma
Ajai Chari,Dan T Vogl,Maria Gavriatopoulou,Ajay K. Nooka,Andrew Yee,Carol Ann Huff,Philippe Moreau,David Dingli,Craig E. Cole,S. Lonial,Meletios A. Dimopoulos,A. Keith Stewart,Joshua Richter,Ravi Vij,Sascha Tuchman,Marc S Raab,Katja Weisel,Michel Delforge,Robert F Cornell,David Kaminetzky,James E. Hoffman,Luciano J. Costa,Terri L. Parker,Moshe Yair Levy,Martin Schreder,Nathalie Meuleman,Laurent Frenzel,Mohamad Mohty,Sylvain Choquet,Gary J. Schiller,Raymond L Comenzo,Monika Engelhardt,Thomas Illmer,Philip Vlummens,Chantal Doyen,Thierry Facon,Lionel Karlin,Aurore Perrot,Klaus Podar,Michael Kauffman,Sharon Shacham,Lingling Li,Shijie Tang,Carla Picklesimer,Jean-Richard Saint-Martin,Marsha Crochiere,Hua Chang,Samir Parekh,Yosef Landesman,Jatin Shah,Paul G. Richardson,Sundar Jagannath +51 more
TL;DR: Selinexor-dexamethasone resulted in objective treatment responses in patients with myeloma refractory to currently available therapies.
Journal ArticleDOI
Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia.
Adriana E. Tron,Matthew A. Belmonte,Ammar Adam,Brian Aquila,Brian Aquila,Lawrence H. Boise,Elisabetta Chiarparin,Justin Cidado,Kevin J. Embrey,Eric Gangl,Francis D. Gibbons,Gareth P. Gregory,Gareth P. Gregory,David J. Hargreaves,J. Adam Hendricks,Jeffrey W. Johannes,Ricky W. Johnstone,Ricky W. Johnstone,Steven L. Kazmirski,Jason Grant Kettle,Michelle Lamb,Shannon M. Matulis,Ajay K. Nooka,Martin J. Packer,Bo Peng,Philip B. Rawlins,Daniel W. Robbins,Alwin Schuller,Nancy Su,Wenzhan Yang,Qing Ye,Xiaolan Zheng,J. Paul Secrist,Edwin Clark,David Matthew Wilson,Stephen Fawell,Alexander Hird +36 more
TL;DR: AZD5991 is a macrocyclic molecule with high selectivity and affinity for Mcl-1 that exhibits potent anti-tumor effects as single agent and in combination with bortezomib or venetoclax in preclinical models of multiple myeloma and acute myeloid leukemia.